These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 3030932)

  • 21. Anti leishmanial therapy--the changing scene.
    Bichile LS
    J Assoc Physicians India; 1994 Sep; 42(9):682-3. PubMed ID: 7883657
    [No Abstract]   [Full Text] [Related]  

  • 22. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
    Sundar S; Murray HW
    J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
    Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
    Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Problems in the treatment of kala-azar: case report.
    Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G; Mbugua J
    East Afr Med J; 1995 Jun; 72(6):406-8. PubMed ID: 7498017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium antimony gluconate, amphotericin, and myocardial damage.
    Thakur CP
    Lancet; 1998 Jun; 351(9120):1928-9. PubMed ID: 9654264
    [No Abstract]   [Full Text] [Related]  

  • 27. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
    Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
    Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
    Giri OP; Singh AN
    J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketoconazole in antimonial unresponsive cases of Kala-azar.
    Jha TK; Singh NK; Jha S
    J Assoc Physicians India; 1995 May; 43(5):347. PubMed ID: 9081966
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of Indian kala-azar with pentavalent antimony.
    Arya SC
    Lancet; 1995 Mar; 345(8949):584. PubMed ID: 7776791
    [No Abstract]   [Full Text] [Related]  

  • 31. The treatment of kala-azar: a review with comments drawn from experience in Kenya.
    Rees PH; Kager PA; Ogada T; Eeftinck Schattenkerk JK
    Trop Geogr Med; 1985 Mar; 37(1):37-46. PubMed ID: 3874454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kala-azar: experience from a non-endemic area in India.
    Chandra J; Anand V; Patwari AK; Mandal RN; Aneja S; Sharma D
    J Trop Pediatr; 1995 Oct; 41(5):298-300. PubMed ID: 8531263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-kala-azar dermal leishmaniasis.
    Ramesh V; Mukherjee A
    Int J Dermatol; 1995 Feb; 34(2):85-91. PubMed ID: 7737782
    [No Abstract]   [Full Text] [Related]  

  • 35. A case of post kala-azar dermal leishmaniasis in India.
    Tripathy K; Misra A; Mallik R; Misra D; Rout N; Rath J
    Korean J Parasitol; 2010 Sep; 48(3):245-6. PubMed ID: 20877504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.
    Mishra M; Biswas UK; Jha AM; Khan AB
    Lancet; 1994 Dec; 344(8937):1599-600. PubMed ID: 7983993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy in Kala-azar.
    Singh NK; Jha TK; Singh IJ; Jha S
    J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
    Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
    Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.